Condition: B Cell Lymphoma · Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
This is a single-arm, open-label clinical study evaluating the efficacy and safety of U01 (ssCART-19) in patients with relapsed or refractory B-cell lymphoma.
This description comes directly from the study's public registry record.
Wenjun Zhang, Ph.D · 13918803148 · zhangwenjun@tongji.edu.cn
Always discuss trial participation with your own doctor first.
| Tongji Hospital of Tongji University | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07093073